– CANADA, Mississauga – Microbix Biosystems Inc. (TSX: MBX | OTC: MBXBF), a life sciences innovator and exporter, today announced the appointment of Anthony Giovinazzo, an accomplished leader in the international life sciences industry, to its Board of Directors, effective immediately.
“I’m delighted to welcome Anthony on behalf of Microbix’s Directors, Management, Staff, and Shareholders. Anthony will add his drive, connectivity, broad perspectives, and expertise to Microbix’s board-level leadership. His selection follows a formal process by which a special committee of our board evaluated multiple qualified candidates.” said Board Chair, Martin Marino.
Anthony will join the Audit Committee and the Human Resources, Compensation & Governance Committee.
About Anthony Giovinazzo
Mr. Giovinazzo has over 40 years of life sciences experience and is an internationally-recognized expert in life sciences intellectual property, drug development, and product commercialization. As CEO of Cynapsus Therapeutics Inc., he co-invented and led the development and commercialization of the now Health Canada and U.S. FDA approved Parkinson’s Disease drug Kynmobi, acquired by Sunovion Pharmaceuticals for CDN$ 841 million in 2016. Among other industry awards, he was the inaugural recipient of the Bloom Burton Award in 2017.
Mr. Giovinazzo is a Chartered Director and is Audit Committee Certified, both from The Directors College, a degree-granting affiliate of McMaster University. He has also completed Harvard Business School’s program for Leadership and Strategy in Pharmaceuticals & Biotech, IMD’s Master of Business Administration program, York University’s Osgoode Hall Law School Certificate Studies in Canadian Law program, and McMaster University’s B.A. of Economics and Accounting program. Mr. Giovinazzo currently serves as executive chairman of Sublimity Therapeutics Ltd., a private company, as a director of Pond Technologies Holdings Inc. (TSXV: POND), and as a director of Titan Medical Inc. (TSX: TMD; NASDAQ: TDMI).
Anthony Giovinazzo said, “I’ve observed how Microbix has been evolving its business and have been impressed. Microbix is now well advanced with its transformation into an inventor, manufacturer, and marketer of innovative, proprietary, branded, and regulated medical devices to support the global diagnostics industry. I look forward to helping to accelerate the pace of value creation by Microbix and ensuring that shareholders are fully rewarded.”
About Microbix Biosystems
Microbix develops proprietary biological and technology solutions for human health and well-being, with about 80 skilled employees and sales growing from a base of approximately $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Microbix antigens enable the antibody tests of over 100 international diagnostics companies, while its QAPs are sold to clinical laboratory accreditation organizations, diagnostics companies, and clinical laboratories. Microbix QAPs are now available in over 20 countries, distributed by Alpha-Tec Systems, Inc., Diagnostic International Distribution S.p.A., Labquality Oy, The Medical Supply Company of Ireland, and R-Biopharm AG. Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed and provides CE marked products.
Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably viral transport media to stabilize patient samples for lab-based molecular diagnostic testing and Kinlytic urokinase, a biologic thrombolytic drug used to treat blood clots. Microbix is traded on the TSX and OTCQB, and headquartered in Mississauga, Ontario, Canada.
For more information: https://microbix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
